Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Danaher Corporation    DHR

DANAHER CORPORATION

(DHR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Danaher : 3Q Profit, Sales Rise

10/22/2020 | 06:40am EST

By Dave Sebastian

Danaher Corp.'s profit and sales for the third quarter grew, the company said Thursday.

For the quarter ended Oct. 2, the conglomerate on Thursday posted net income before preferred dividends of $883.5 million, or $1.16 a share, compared with $668 million, or 84 cents a share, in the year-ago period.

One of the company's units earlier this month said its Covid-19 antibody test got emergency use authorization from the Food and Drug Administration. The company didn't immediately provide details of Covid-19 effects in its earnings release Thursday.

Adjusted earnings were $1.72 a share. Analysts polled by FactSet were looking for earnings of $1.01 a share, or $1.36 a share on an adjusted basis.

Sales rose to $5.88 billion from $4.38 billion in the comparable quarter last year. Analysts were looking for $5.51 billion. Core revenue, including Cytiva, rose 14%. The company had expected third-quarter core revenue growth, including Cytiva, to be in the mid- to high-single digit range.

Danaher said it expects fourth-quarter core revenue growth, including Cytiva, to be in the low-double digit range.

Write to Dave Sebastian at dave.sebastian@wsj.com

(END) Dow Jones Newswires

10-22-20 0639ET

All news about DANAHER CORPORATION
11/25DANAHER : to Present at Evercore ISI HealthCONx Conference
AQ
11/24DANAHER : To Present At Evercore ISI HealthCONx Conference
PR
11/23DANAHER : Beckman Coulter launches its semi-quantitative SARS-CoV-2 IgG II antib..
PR
11/17DANAHER : to Present at Wolfe Research Healthcare Conference
AQ
11/16DANAHER : To Present At Wolfe Research Healthcare Conference
PR
11/11DANAHER : Releases 2020 Sustainability Report
AQ
11/10DANAHER : Releases 2020 Sustainability Report
PR
11/10DANAHER : Beckman Coulter launches its SARS-CoV-2 IgM antibody test in countries..
PR
10/27DANAHER : Cytiva strengthens support to diagnostics industry with new labs, serv..
AQ
10/23DANAHER : Reports Third Quarter 2020 Results
AQ
More news
Financials (USD)
Sales 2020 21 957 M - -
Net income 2020 3 386 M - -
Net Debt 2020 16 070 M - -
P/E ratio 2020 48,1x
Yield 2020 0,32%
Capitalization 160 B 160 B -
EV / Sales 2020 8,00x
EV / Sales 2021 6,81x
Nbr of Employees 60 000
Free-Float 74,1%
Chart DANAHER CORPORATION
Duration : Period :
Danaher Corporation Technical Analysis Chart | DHR | US2358511028 | MarketScreener
Technical analysis trends DANAHER CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Average target price 249,50 $
Last Close Price 224,63 $
Spread / Highest target 24,6%
Spread / Average Target 11,1%
Spread / Lowest Target -38,6%
EPS Revisions
Managers
NameTitle
Rainer M. Blair President, Chief Executive Officer & Director
Steven M. Rales Chairman
Matthew R. McGrew Chief Financial Officer & Executive Vice President
Alan G. Spoon Independent Director
Walter G. Lohr Independent Director
Sector and Competitors